About Us

Leadership Team

Our senior management team’s leadership and vision are critical to the company’s operational efficiency and growth, positioning us well to continue bringing important therapeutics to patients in need.

William K. Heiden
President and Chief Executive Officer
William Heiden is an experienced pharmaceutical and biotechnology executive who has been chief executive officer and president of AMAG since...
William Heiden is an experienced pharmaceutical and biotechnology executive who has been chief executive officer and president of AMAG since May 2012. Mr. Heiden joined AMAG from GTC Biotherapeutics, Inc. (now rEVO Biologics, Inc.), where he was president and chief executive officer from 2010 to 2012 and chairman of the board of directors from 2007 to 2013. From 2004 to 2008, Mr. Heiden was the president and chief executive officer and a member of the board of directors of Elixir Pharmaceuticals. Prior to that, Mr. Heiden served as president and chief operating officer of Praecis Pharmaceuticals Incorporated (now GlaxoSmithKline plc). Mr. Heiden also held various positions of increasing responsibility at Schering-Plough Corporation (now Merck & Co.), including managing a number of businesses in the United States, Europe and Canada. He currently serves on the board of directors for Atara Biotherapeutics, Inc. Mr. Heiden holds a Bachelor of Arts degree from the University of Florida, a Master of Information Management from the University of Louvain, and a Master of Business Administration from Cornell University’s Johnson Graduate School of Management.
Tony Casciano
Executive Vice President, Chief Commercial Officer
Tony Casciano serves as AMAG’s chief commercial officer, bringing nearly 20 years of commercial sales and marketing experience. He joined...
Tony Casciano serves as AMAG’s chief commercial officer, bringing nearly 20 years of commercial sales and marketing experience. He joined AMAG in September 2016 and has since held positions of increasing responsibility in the company. Prior to AMAG, Mr. Casciano served as the head of marketing for General Medicines at Sanofi . During his 16 year career at Sanofi, he held multiple commercial leadership roles across a broad range of departments and therapeutic areas. He was also responsible for building and leading top-performing cross-functional commercial teams to achieve aggressive goals for more than a dozen specialty brands. Mr. Casciano holds a Bachelor of Science degree in business administration from Bridgewater State College.
Julie Krop, M.D.
Executive Vice President, Chief Medical Officer
Julie Krop, M.D. serves as AMAG’s chief medical officer and executive vice president of clinical development and regulatory affairs. She...
Julie Krop, M.D. serves as AMAG’s chief medical officer and executive vice president of clinical development and regulatory affairs. She joined AMAG in June 2015 and has more than 15 years of experience in drug development. Dr. Krop most recently worked for Vertex Pharmaceuticals, where she served as vice president of clinical development. She began her career in the biopharmaceutical industry in 1991 at Pfizer, Inc. and has since held various leadership positions at Stryker Regenerative Medicine, Peptimmune, and Millennium Pharmaceuticals. Dr. Krop received a Bachelor of Science degree from Brown University and a medical degree from the Brown University School of Medicine. She completed her residency in the Department of Medicine at Georgetown University Hospital and a fellowship in the Department of Endocrinology at The Johns Hopkins University School of Medicine. In addition, Dr. Krop was a Robert Wood Johnson Foundation Clinical Scholar.
Edward (Ted) Myles
Executive Vice President, Chief Financial Officer & Chief Operating Officer
Ted Myles serves as AMAG’s executive vice president, chief financial officer & chief operating officer. He joined AMAG in 2016 and...
Ted Myles serves as AMAG’s executive vice president, chief financial officer & chief operating officer. He joined AMAG in 2016 and brings more than 20 years of public and private corporate finance and operational experience in the biotechnology, pharmaceutical and medical device industries. Prior to joining AMAG, he served in various positions at Ocata Therapeutics, Inc., most recently as chief financial officer and chief operating officer. During his tenure at Ocata, he led the turnaround of the company, which ultimately resulted in its acquisition by Astellas Pharma in February 2016. From 2008 to 2013, Mr. Myles served as chief financial officer and vice president of operations at PrimeraDx, Inc. Mr. Myles also served as controller at EMD Pharmaceuticals, Inc., a wholly-owned subsidiary of Merck KGaA. Earlier in his career, Mr. Myles was an associate in the healthcare investment banking group at SG Cowen Securities Corporation and was a senior associate in the audit practice of Coopers & Lybrand LLP. Mr. Myles currently serves on the board of directors of Scholar Rock Holdings (NASDAQ: SRRK), a biotechnology company. Mr. Myles holds a Bachelor of Science in Business Administration BSBA from the University of Hartford and a Master of Business Administration from The John M. Olin School of Business at Washington University.
Kelly Schick
Senior Vice President, Chief Human Resources Officer
Kelly Schick serves as AMAG’s senior vice president and chief human resources officer. She joined AMAG in September 2016 and has more than...
Kelly Schick serves as AMAG’s senior vice president and chief human resources officer. She joined AMAG in September 2016 and has more than 15 years of human resource experience in the pharmaceutical industry. Prior to AMAG, Ms. Schick served as head of global talent for Bristol-Myers Squibb (BMS) where she had responsibility for global talent management, talent acquisition, learning and development, organization effectiveness and diversity and inclusion for the company's global manufacturing division. Before joining BMS in 2011, Ms. Schick held a series of HR business partner roles of increasing responsibility supporting the research and development organization for Merck and Company, Inc. Ms. Schick holds a Bachelor of Arts in psychology from Boston University and a Master of Arts in human resources and labor relations from the Curtis L. Carlson School of Management at the University of Minnesota.
Joseph D. Vittiglio
Executive Vice President, General Counsel, Chief Business Officer & Quality & Corporate Secretary
Joseph Vittiglio serves as AMAG’s executive vice president, general counsel, chief business officer and quality and corporate secretary....
Joseph Vittiglio serves as AMAG’s executive vice president, general counsel, chief business officer and quality and corporate secretary. Before joining AMAG, he served as vice president of legal affairs and a member of the management committee at Flexion Therapeutics, Inc. Prior to that, Mr. Vittiglio was the general counsel of AVEO Pharmaceuticals and the director of legal affairs at Oscient Pharmaceuticals Corporation. He began his legal career as an associate attorney at Gaffin & Krattenmaker, P.C., before joining Mintz, Levin, Cohn, Ferris, Glovsky and Popeo PC as a senior attorney in 1998. Mr. Vittiglio holds a Bachelor of Science degree in international relations from Tufts University and a Juris Doctor from Northeastern University School of Law.